FDA touts new au­thor­i­ty as ODAC hosts ad­comm to re­view de­layed con­fir­ma­to­ry tri­als for ac­cel­er­at­ed ap­provals

The FDA’s On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee will meet Thurs­day to look at two can­cer drugs that first won ac­cel­er­at­ed ap­proval in 2009 and 2014 but have failed to com­plete their con­fir­ma­to­ry tri­als.

The two drugs are both in­di­cat­ed for re­lapsed or re­frac­to­ry pe­riph­er­al T cell lym­phoma (PT­CL) and from Acrotech Bio­phar­ma: Folo­tyn (prala­trex­ate) and Beleo­daq (be­li­no­s­tat).

The agency not­ed in brief­ing doc­u­ments re­leased Tues­day ahead of the meet­ing that there have been “sub­stan­tial de­lays” in an up­dat­ed con­fir­ma­to­ry tri­al the spon­sor pro­posed, as well as,

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER